NetraMark Holdings Inc. announced the appointment of Dr. MaryAnne Rizk to its strategic advisory board. With her significant industry experience and expertise, MaryAnne's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based offerings and drive business growth. Dr. Rizk is a highly accomplished professional with a career spanning over two decades.

She has held key leadership roles in renowned organizations including Chief Strategy Officer at Medable, Sr. VP at IQVIA, Global VP CRO Strategic Alliance Partner Business at Oracle and Global Program Director at Medidata Solutions. Dr. Rizk was awarded with the PharmaVOICE 100 most inspiring leaders as a leading change agent in 2021. Dr. Rizk has a deep understanding of the evolving pharmaceutical industry landscape with expertise in digital, data and driving innovation across partnerships which makes her a valuable asset to the NetraMark advisory board.

Dr. Rizk serves on a number of industry advisory councils and memberships including Chief, CNS Summit, Decentralized Trials Research Alliance (DTRA), Drug Information Association (DIA), Forbes Tech Council and the Galien Foundation. She earned her PhD, Masters and Bachelor of Engineering at Stevens Institute of Technology and has focused her expertise to provide the biopharma industry access to leading innovations that provide the acceleration of drug development to patients powered by innovative SaaS platforms. As a member of the NetraMark advisory board, Dr. Rizk will play an important role in guiding the Company's strategic direction, leveraging her expertise to enhance NetraMark's industry presence. Her market knowledge and proven track record in driving growth will empower NetraMark to accelerate the utilization of AI within the clinical trial process.